What is the recommended treatment for a patient with a heavy growth of Morganella morganii, which is resistant to multiple antibiotics, including Ampicillin, Amoxicillin/Clavulanic Acid, and others, but sensitive to Piperacillin/Tazobactam, Cefoperazone/Sulbactam, Cefepime, Imipenem, and Meropenem?

Treatment of Multidrug-Resistant Morganella morganii Infection

For this heavily resistant Morganella morganii isolate, use either piperacillin-tazobactam 4.5 g IV every 6 hours or a carbapenem (meropenem 1 g IV every 8 hours or imipenem 500 mg IV every 6 hours) as definitive therapy, with the choice depending on infection site and severity. 1

Recommended Treatment Algorithm

First-Line Options (Based on Susceptibility)

For most infections:

• Piperacillin-tazobactam 4.5 g IV every 6 hours is the preferred agent given its excellent susceptibility profile and lower resistance selection pressure compared to carbapenems 1, 2
• This agent showed only 1.8% resistance rates in M. morganii bacteremia studies and is recommended for empiric coverage of gram-negative infections 3

For severe infections or ICU patients:

• Meropenem 1 g IV every 8 hours by extended infusion (infused over 3 hours) 1
• Imipenem 500 mg IV every 6 hours 1
• Carbapenems are particularly important given the resistance to third-generation cephalosporins (ceftriaxone, cefotaxime), which suggests possible AmpC β-lactamase production 2, 4

Alternative Option

• Cefepime 2 g IV every 8 hours can be used as it shows susceptibility, though it is less preferred than piperacillin-tazobactam or carbapenems for serious infections 1

Duration of Therapy by Infection Site

Bloodstream infections: 7-14 days 1

Complicated urinary tract infections: 5-7 days 1

Skin and soft tissue infections: 7-10 days 5

Complicated intra-abdominal infections: 5-7 days 1

Critical Clinical Considerations

Resistance Pattern Analysis

This isolate demonstrates an extremely concerning multidrug-resistant profile with resistance to:

• All aminoglycosides (gentamicin, amikacin) - eliminating combination therapy options 3
• All fluoroquinolones (ciprofloxacin, levofloxacin) 3
• Tigecycline - unusual and particularly worrisome 4
• Extended-spectrum resistance including third-generation cephalosporins, suggesting AmpC β-lactamase production 2, 4

Infectious Disease Consultation

Strongly recommended given the extensive resistance pattern and potential for treatment failure 1

Source Control

Mandatory for optimal outcomes - this includes:

• Drainage of abscesses 5
• Removal of infected catheters or foreign bodies 1
• Surgical debridement of infected tissue when indicated 5
• Without adequate source control, antibiotic therapy alone has limited efficacy 6

Prognostic Factors and Monitoring

High-Risk Features for Mortality (41% in-hospital mortality reported)

• ICU admission (OR 4.4) 3
• Age >65 years 6, 3
• Elevated blood urea nitrogen 3
• APACHE II score (most significant predictor, OR 1.55-1.62) 3
• Co-infection with other organisms 6

Clinical Monitoring

• Assess clinical response within 48-72 hours 7
• If no improvement, consider alternative therapy or inadequate source control 7
• Monitor renal function closely, especially with carbapenem therapy 8

Important Caveats

Do not use:

• Ampicillin-sulbactam or amoxicillin-clavulanate - M. morganii has intrinsic resistance to these agents 2, 3
• Aminoglycoside monotherapy - this isolate is resistant 3
• First-generation cephalosporins - ubiquitous resistance in M. morganii 3

Avoid carbapenem-sparing strategies in this case given the extensive resistance profile and lack of alternative options 1

Polymicrobial infection consideration: M. morganii is part of polymicrobial infections in 58% of cases, so ensure coverage addresses all identified pathogens 5

Extended infusion of beta-lactams is recommended for organisms with higher MICs to optimize time above MIC, the key pharmacodynamic parameter 1, 8